SEC Form 3 filed by new insider Akselbrad Dikla Czaczkes
$PYPD
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 934 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock option (right to buy) | 07/05/2016 | 04/05/2026 | Ordinary Shares | 279(1) | $92.89 | D | |
| Stock option (right to buy) | 08/25/2017 | 08/24/2026 | Ordinary Shares | 228(2) | $92.89 | D | |
| Stock option (right to buy) | 03/21/2017 | 12/21/2026 | Ordinary Shares | 1,713(3) | $117.99 | D | |
| Stock option (right to buy) | 08/08/2023 | 05/05/2033 | Ordinary Shares | 2,833(4) | $23.07 | D | |
| Stock option (right to buy) | 10/01/2019 | 06/11/2030 | Ordinary Shares | 3,187(5) | $23.07 | D | |
| Stock option (right to buy) | 08/09/2022 | 08/09/2032 | Ordinary Shares | 1,827(6) | $23.07 | D | |
| Stock option (right to buy) | 07/01/2023 | 05/03/2032 | Ordinary Shares | 3,333(7) | $23.07 | D | |
| Stock option (right to buy) | 08/07/2024 | 10/09/2033 | Ordinary Shares | 30,486(8) | $11.01 | D | |
| Stock option (right to buy) | 08/06/2024 | 07/02/2034 | Ordinary Shares | 198,900(9) | $4.64 | D | |
| Stock option (right to buy) | 06/09/2025 | 07/02/2034 | Ordinary Shares | 132,600(10) | $4.64 | D | |
| Stock option (right to buy) | 08/12/2025 | 06/25/2035 | Ordinary Shares | 120,000(11) | $2.67 | D | |
| Stock option (right to buy) | 06/09/2025 | 06/25/2035 | Ordinary Shares | 80,000(12) | $2.67 | D | |
| Explanation of Responses: |
| 1. The options were granted on April 5, 2016 and fully vested as of April 5, 2019. |
| 2. The options were granted on August 24, 2016 and fully vested as of August 24, 2019. |
| 3. The options were granted on December 21, 2016 and fully vested as of December 21, 2019. |
| 4. The options were granted on May 5, 2023 and vest on a quarterly basis until May 5, 2027. |
| 5. The options were granted on June 11, 2020 and fully vested as of July 1, 2022. |
| 6. The options were granted on August 9, 2021 and vest on a quarterly basis beginning August 9, 2022 until August 9, 2025. |
| 7. The options were granted on May 3, 2022 and fully vested as of April 1, 2025. |
| 8. The options were granted on October 9, 2023 and vest on a quarterly basis beginning August 7, 2024 until August 7, 2027. |
| 9. The options were granted on July 2, 2024 and vest on a quarterly basis until May 6, 2028. |
| 10. The options were granted on July 2, 2024 and vest on a quarterly basis until May 6, 2026. |
| 11. The options were granted on June 25, 2025 and vest on a quarterly basis until May 12, 2029. |
| 12. The options were granted on June 25, 2025 and vest on a quarterly basis until May 12, 2027. |
| /s/ Dikla Czaczkes Akselbrad | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||